Immunocore IMCR Stock
Immunocore Price Chart
Immunocore IMCR Financial and Trading Overview
| Immunocore stock price | 34.68 USD |
| Previous Close | 31.95 USD |
| Open | 31.73 USD |
| Bid | 23.89 USD x 200 |
| Ask | 39.92 USD x 200 |
| Day's Range | 30.29 - 33.29 USD |
| 52 Week Range | 27.56 - 40.72 USD |
| Volume | 881.52K USD |
| Avg. Volume | 476.9K USD |
| Market Cap | 1.65B USD |
| Beta (5Y Monthly) | 0.729 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.58 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 63.37 USD |
IMCR Valuation Measures
| Enterprise Value | 1.24B USD |
| Trailing P/E | N/A |
| Forward P/E | -51.984 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.0033298 |
| Price/Book (mrq) | 4.194965 |
| Enterprise Value/Revenue | 3.012 |
| Enterprise Value/EBITDA | -109.368 |
Trading Information
Immunocore Stock Price History
| Beta (5Y Monthly) | 0.729 |
| 52-Week Change | -9.49% |
| S&P500 52-Week Change | 20.84% |
| 52 Week High | 40.72 USD |
| 52 Week Low | 27.56 USD |
| 50-Day Moving Average | 29.56 USD |
| 200-Day Moving Average | 32.51 USD |
IMCR Share Statistics
| Avg. Volume (3 month) | 476.9K USD |
| Avg. Daily Volume (10-Days) | 643.18K USD |
| Shares Outstanding | 50.87M |
| Float | 42.46M |
| Short Ratio | 15.66 |
| % Held by Insiders | 0.066% |
| % Held by Institutions | 104.46% |
| Shares Short | 8.99M |
| Short % of Float | 19.67% |
| Short % of Shares Outstanding | 17.67% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | -6.67% |
| Operating Margin (ttm) | 6.82% |
| Gross Margin | 32.27% |
| EBITDA Margin | -2.75% |
Management Effectiveness
| Return on Assets (ttm) | -0.87% |
| Return on Equity (ttm) | -7.14% |
Income Statement
| Revenue (ttm) | 412.81M USD |
| Revenue Per Share (ttm) | 8.17 USD |
| Quarterly Revenue Growth (yoy) | 13.60% |
| Gross Profit (ttm) | 133.25M USD |
| EBITDA | -11369000 USD |
| Net Income Avi to Common (ttm) | -27566000 USD |
| Diluted EPS (ttm) | -0.56 |
| Quarterly Earnings Growth (yoy) | 158.20% |
Balance Sheet
| Total Cash (mrq) | 844.9M USD |
| Total Cash Per Share (mrq) | 16.61 USD |
| Total Debt (mrq) | 435.68M USD |
| Total Debt/Equity (mrq) | 110.67 USD |
| Current Ratio (mrq) | 4.181 |
| Book Value Per Share (mrq) | 7.745 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -24922000 USD |
| Levered Free Cash Flow (ttm) | 58.58M USD |
Profile of Immunocore
| Country | United States |
| State | N/A |
| City | Abingdon |
| Address | 92 Park Drive |
| ZIP | OX14 4RY |
| Phone | 44 12 3543 8600 |
| Website | https://www.immunocore.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 524 |
Immunocore Holdings plc, together with its subsidiaries, engages in the development and commercialization of immunomodulating medicines for patients with cancer, infectious diseases, and autoimmune disease in the United States, Europe, and internationally. The company offers KIMMTRAK for the treatment of unresectable or metastatic uveal melanoma. It also develops oncology programs, including tebentafusp which is in Phase 3 clinical trial for the treatment of advanced cutaneous melanoma and adjuvant uveal melanoma; brenetafusp which is in Phase 3 clinical trial for the treatment of first-line advanced cutaneous melanoma and in Phase 1/2 clinical trial for the treatment of various tumor types; IMC-R117C which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors, such as colorectal cancer; and IMC-P115C which is in Phase 1 clinical trial for patients with tumors that express PRAME. In addition, the company is involved in the development of IMC-M113V which is in Phase 1 clinical trial for a potential functional cure of human immunodeficiency virus; and IMC-I109V which is in Phase 1 clinical trial for a potential functional cure of hepatitis B virus. Further, it develops IMC-S118AI which is in pre-investigation stage for the treatment of type 1 diabetes; and IMC-U120AI which is in pre-investigation stage for the treatment of atopic dermatitis. The company was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
Q&A For Immunocore Stock
What is a current IMCR stock price?
Immunocore IMCR stock price today per share is 34.68 USD.
How to purchase Immunocore stock?
You can buy IMCR shares on the Tech Market Large exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Immunocore?
The stock symbol or ticker of Immunocore is IMCR.
Which industry does the Immunocore company belong to?
The Immunocore industry is Biotechnology.
How many shares does Immunocore have in circulation?
The max supply of Immunocore shares is 50.87M.
What is Immunocore Price to Earnings Ratio (PE Ratio)?
Immunocore PE Ratio is now.
What was Immunocore earnings per share over the trailing 12 months (TTM)?
Immunocore EPS is -0.58 USD over the trailing 12 months.
Which sector does the Immunocore company belong to?
The Immunocore sector is Healthcare.
Immunocore IMCR included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
|
|
{{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
US Tech Composite
IXIC
US
|
26269.23 USD — |
+0.62
|
6.33B USD — | 26041.13 USD — | 26316.81 USD — | — - | 6.33B USD — |
|
Stlmt ID US Tech Biotechnology
NBX
US
|
3995.9 USD — |
-4.37
|
— — | 4555.41 USD — | 4917.8 USD — | — - | — — |
|
US Tech Global Select Market Com
NQGS
US
|
12896.68 USD — |
+0.63
|
— — | 12785.35 USD — | 12920.04 USD — | — - | — — |
|
US Tech Biotechnology
NBI
US
|
6562.03 USD — |
+0.7
|
— — | 6454.97 USD — | 6563.4 USD — | — - | — — |
|
US Tech Health Care
IXHC
US
|
1251.97 USD — |
+0.86
|
— — | 1233.72 USD — | 1252.49 USD — | — - | — — |
- {{ link.label }} {{link}}